Blanket Purchase Agreement 36F79722D0090-36E79722A0019
Award Date
5/1/22
Last Date to Order
4/30/26
Federal Agency
National Acquisition Center
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The key products and services being delivered under this federal contract IDV are specialized pharmaceutical and vaccine products, primarily focused on PROLASTIN-C, an alpha1-proteinase inhibitor used to treat alpha1-antitrypsin deficiency. The prime contractor, Grifols USA LLC, is a global healthcare company that specializes in the development, manufacturing, and distribution of plasma-derived medicines and other pharmaceutical supplies. The contract IDV consists of a $1.38 billion Federal...
The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit pharmaceutical company. The FSS contract, which has a ceiling value of $4,958,982,930 and a period of performance through May 31, 2028, is for the procurement of drugs, pharmaceuticals, and hematology-related products. The contract also includes a single-award Blanket Purchase Agreement (BPA) with a...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency under the Department of Veterans Affairs (VA), to Biocryst Pharmaceuticals Inc. The BPA has a ceiling value of $10,000,000 and an ultimate completion date of May 18, 2026. It is a single-award contract awarded under GSA Schedule 61-IB for Pharmaceuticals and Drugs, with no set-aside used. The BPA is for the procurement of two pharmaceutical products: RAPIVAB (peramivir),...
The federal contract IDV is a multiple-award Federal Supply Schedule contract with the Department of Veterans Affairs (VA) for the procurement of pharmaceutical products, medical supplies, and vaccines. The contract has a total ceiling value of $3.9 billion and a period of performance through July 31, 2027. The prime contractor is Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company that provides a range of medical products to various federal agencies. Under this IDV,...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Boehringer Ingelheim Pharmaceuticals Inc. The contract is for the procurement of drugs, pharmaceuticals, and hematology-related products, with a ceiling value of $5,020,461,140.00. The period of performance extends from the award date of September 15, 2022, to the ultimate completion date of September 14, 2027. As a multiple award FSS contract, this vehicle allows the VA and...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a component of the Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA, valued at $83.5 million, is for a one-year period from May 2024 to May 2025. The BPA covers the procurement of specialized medications used to treat pulmonary arterial hypertension, including Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, and...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs National Acquisition Center to Rare Disease Therapeutics, Inc., a woman-owned small business. The BPA, valued at $250,000, is based on the company's GSA Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and has an ultimate completion date of May 31, 2026. This single-award BPA allows the VA to access Rare Disease Therapeutics' catalog of specialty pharmaceutical products,...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, awarded by the Veterans Integrated Service Network 12 (VISN 12) of the U.S. Department of Veterans Affairs (VA). The prime contractor is Amphastar Pharmaceuticals, Inc., a for-profit manufacturer of pharmaceutical goods. The $58,244,500 multiple award contract has a period of performance through January 14, 2027 and aims to procure a broad range of drug,...
The federal contract Indefinite Delivery Vehicle (IDV) is a $4.41 billion Federal Supply Schedule contract awarded by the Veterans Integrated Service Network 12 to Janssen Pharmaceuticals, Inc. The contract covers the delivery of drugs, pharmaceuticals, and hematology-related products to federal agencies, with a focus on supporting the medical needs of military and veterans' healthcare systems. As the prime contractor, Janssen Pharmaceuticals, a for-profit manufacturer of pharmaceutical goods...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule, with a ceiling value of $2,210,000,000 and a period of performance through September 2026. Biogen has been awarded multiple firm-fixed-price delivery orders against this FSS contract for the supply of specialized...